Compare Johnson & Johnson (JNJ) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Schlumberger NV — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Schlumberger NV trades at $48.95 (market cap $72.69B). The key difference: Johnson & Johnson is far larger — about 8.5× Schlumberger NV's market cap, and Schlumberger NV pays the higher dividend (2.41%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Schlumberger NV for 99 Days on average.
| JNJ | SLB | |
|---|---|---|
Market Cap | $618.09B | $72.69B |
Volume | 6,050,983 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $278.43 | $60.10 |
52-Week Low | $186.00 | $31.72 |
Typical Hold Time | 129 Days | 99 Days |
Enterprise Value | $646.37B | $81.42B |
Dividend Yield | 2.09% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
SLB trades at $48.98, up 2.13% today, with strong analyst support (85% buy ratings) and a $64.58 consensus price target suggesting 32% upside. Recent contract wins in Saudi Arabia, Oman, and Mozambique expand revenue visibility, though technical indicators show bearish momentum. The company maintains solid profitability with 8.53% net margins and consistent earnings beats in recent quarters.
SLB's multi-year contracts provide stable revenue streams, but declining profit margins and bearish technicals present near-term headwinds. The stock offers value with reasonable valuation multiples (P/E 23.89) and dividend income, though energy sector volatility and execution risks on new projects require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
